Darolutamide FDA Approval: Prostate Cancer Treatment
- Teh Food and Drug Administration has given the green light to darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals) for treating metastatic castration-sensitive prostate cancer (mCSPC), expanding its indications.
- further analysis from the ARANOTE trial, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, revealed that darolutamide plus ADT notably improves health-related quality of...
- In the ARANOTE study, the median rPFS was not reached in the darolutamide group (n = 446), while the placebo group (n = 223) had a median rPFS...
The FDA has approved darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC),a pivotal advancement for men battling this condition. This decision, based on the ARANOTE trial, reveals darolutamide significantly enhances radiographic progression-free survival (rPFS) when used with androgen deprivation therapy (ADT). The study, highlighted at the ASCO meeting, also demonstrates that darolutamide improves health-related quality of life (HRQOL) and delays the progression of pain in patients with mCSPC, offering a more promising outlook. News Directory 3 is committed to bringing you the latest updates on cancer treatments. In the ARANOTE trial, darolutamide demonstrated impressive results, consistently improving outcomes across subgroups.The results also show a favorable trend in overall survival and significant delays in critical disease markers. Discover what’s next for darolutamide and prostate cancer treatment.
FDA Approves Darolutamide for Metastatic Prostate Cancer
Teh Food and Drug Administration has given the green light to darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals) for treating metastatic castration-sensitive prostate cancer (mCSPC), expanding its indications. The approval hinges on phase 3 ARANOTE trial data, which demonstrated substantially improved radiographic progression-free survival (rPFS) when darolutamide was combined with androgen deprivation therapy (ADT), compared to a placebo plus ADT.
further analysis from the ARANOTE trial, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, revealed that darolutamide plus ADT notably improves health-related quality of life (HRQOL) and delays pain progression in mCSPC patients.
Image credit: wladimir1804 – stock.adobe.com
In the ARANOTE study, the median rPFS was not reached in the darolutamide group (n = 446), while the placebo group (n = 223) had a median rPFS of 25.0 months (HR, 0.54; 95% CI, 0.41–0.71; P < .0001). After 24 months, 70.3% of darolutamide-treated patients were free from radiographic progression, compared to 52.1% in the placebo group. The rPFS benefits were consistent across subgroups.
Although overall survival (OS) did not reach statistical importance (HR, 0.78; 95% CI,0.58–1.05), a favorable trend emerged, with 24-month OS rates of 79.8% for darolutamide versus 75.5% for placebo.
Secondary endpoints reinforced the clinical benefit of darolutamide. The treatment significantly delayed the time to metastatic castration-resistant prostate cancer (mCRPC; HR 0.40), PSA progression (HR, 0.31), and the need for subsequent systemic anticancer therapy (HR, 0.40). A higher proportion of patients on darolutamide achieved deep PSA suppression, with 62.6% reaching levels below 0.2 ng/mL, compared to 18.5% in the placebo group. darolutamide also delayed the time to pain progression (HR,0.72).
“These results from the ARANOTE trial highlight the potential of darolutamide to not only extend radiographic progression-free survival for patients with metastatic castration-sensitive prostate cancer, but to do so while creating clinically meaningful delays in deterioration of quality of life compared to ADT alone,” said Dr.Alicia K. Morgans of the Dana-Farber Cancer Institute.
The safety profile of darolutamide remained consistent with prior data. Common grade 3 or 4 adverse events included hypertension (3.6%), anemia (3.6%), and pain in extremities (1.8%). Warnings include ischemic heart disease, seizure, and embryo-fetal toxicity. The approved dose is 600 mg daily, as two 300-mg tablets taken orally twice daily with food.
What’s next
This approval provides a new option for men with mCSPC, a condition with limited long-term survival. The ARANOTE data underscore the drug’s value in improving disease control and delaying progression markers.